Intercultural Facts About Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 12
Volume 10
Issue 12

HOUSTON-The Intercultural Cancer Council (ICC) promotes policies, programs, partnerships, and research to eliminate the unequal burden of cancer among racial and ethnic minorities and medically underserved populations in the United States and its associated territories. With this issue, ONI launches a regular column devoted to intercultural facts about cancer, based on information from the ICC and other sources.

HOUSTON—The Intercultural Cancer Council (ICC) promotes policies, programs, partnerships, and research to eliminate the unequal burden of cancer among racial and ethnic minorities and medically underserved populations in the United States and its associated territories. With this issue, ONI launches a regular column devoted to intercultural facts about cancer, based on information from the ICC and other sources.

Minorities Become Majority

Racial and ethnic minorities and medically underserved populations experience disproportionately greater suffering and death from cancer, as compared with the US population as a whole. The ICC believes this is of paramount importance because, as minorities continue to grow at a rapid rate, these groups as a whole will become the "majority" population.

According to the ICC, reasons for disparities in the health status of these groups include the following:

  • Unequal socioeconomic status, resulting in unequal availability, accessibility, and utilization of health services.

  • Unequal diagnostic workup and treatment after entry into the health care system.

  • Unequal scientific research, resulting in unequal data collection and unequal understanding of their medical needs.

  • Social, racial, and environmental injustice.

  • Individual as well as institutional prejudice and discrimination.

The effects of all these factors together are compounded by the inability—or the unwillingness—of society to acknowledge their existence, persistence, and adverse impact, the ICC states.

In the coming months, ONI will explore these and other issues related to minorities and cancer, and will report on the ICC’s 8th Biennial Symposium on Minorities, the Medically Underserved & Cancer, to be held in Washington, DC, February 6-10, 2002. For more information, see iccnetwork.org

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content